Otonomy, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for otology in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; and OTO- 313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. In addition, it develops OTO-413, a sustained exposure formulation of brain-derived neurotrophic factor for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties; OTO-5XX, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OTIC
CUSIPN/A
Phone619-323-2200
Debt
Debt-to-Equity RatioN/A
Current Ratio16.24
Quick Ratio16.24
Price-To-Earnings
Trailing P/E Ratio-1.46
Forward P/E Ratio-2.44
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.24 million
Price / Sales107.28
Cash FlowN/A
Price / CashN/A
Book Value$3.87 per share
Price / Book1.12
Profitability
EPS (Most Recent Fiscal Year)($2.97)
Net Income$-90,130,000.00
Net Margins-6,316.88%
Return on Equity-58.60%
Return on Assets-53.72%
Miscellaneous
Employees53
Outstanding Shares30,580,000
Otonomy (NASDAQ:OTIC) Frequently Asked Questions
What is Otonomy's stock symbol?
Otonomy trades on the NASDAQ under the ticker symbol "OTIC."
How were Otonomy's earnings last quarter?
Otonomy Inc (NASDAQ:OTIC) issued its quarterly earnings results on Thursday, March, 8th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.05. The biopharmaceutical company earned $0.27 million during the quarter, compared to analyst estimates of $0.46 million. Otonomy had a negative net margin of 6,316.88% and a negative return on equity of 58.60%. The company's revenue was down 1.1% on a year-over-year basis. View Otonomy's Earnings History.
What price target have analysts set for OTIC?
4 Wall Street analysts have issued 12-month target prices for Otonomy's shares. Their predictions range from $8.00 to $15.00. On average, they anticipate Otonomy's share price to reach $10.00 in the next twelve months. View Analyst Ratings for Otonomy.
Who are some of Otonomy's key competitors?
Some companies that are related to Otonomy include Stemline Therapeutics (STML), TIGENIX/S (TIG), AC Immune (ACIU), Achaogen (AKAO), Zymeworks (ZYME), Rigel Pharmaceuticals (RIGL), ZIOPHARM Oncology (ZIOP), Aurinia Pharmaceuticals (AUPH), Merus (MRUS), Verastem (VSTM), ArQule (ARQL), Sinovac Biotech (SVA), Depomed (DEPO), ZEALAND PHARMA/S (ZEAL) and Concert Pharmaceuticals (CNCE).
Who are Otonomy's key executives?
Otonomy's management team includes the folowing people:
- Dr. Jay B. Lichter, Co-Founder & Chairman (Age 56)
- Dr. David Allen Weber, Pres, CEO & Director (Age 58)
- Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 56)
- Dr. Kathie M. Bishop, Chief Scientific Officer (Age 52)
- Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel
Has Otonomy been receiving favorable news coverage?
News coverage about OTIC stock has trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Otonomy earned a news impact score of 0.07 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.67 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Otonomy's major shareholders?
Otonomy's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.77%), Dimensional Fund Advisors LP (3.68%), JPMorgan Chase & Co. (0.87%), Millennium Management LLC (0.38%), Sofinnova Ventures Inc (0.32%) and A.R.T. Advisors LLC (0.21%). Company insiders that own Otonomy stock include Carl Lebel and Eric J Loumeau. View Institutional Ownership Trends for Otonomy.
Which institutional investors are selling Otonomy stock?
Which institutional investors are buying Otonomy stock?
OTIC stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Dimensional Fund Advisors LP, Sofinnova Ventures Inc, Trexquant Investment LP and BlackRock Inc.. View Insider Buying and Selling for Otonomy.
How do I buy shares of Otonomy?
Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Otonomy's stock price today?
One share of OTIC stock can currently be purchased for approximately $4.35.
How big of a company is Otonomy?
Otonomy has a market capitalization of $136.07 million and generates $1.24 million in revenue each year. The biopharmaceutical company earns $-90,130,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. Otonomy employs 53 workers across the globe.
How can I contact Otonomy?
Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]
MarketBeat Community Rating for Otonomy (OTIC)
MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe OTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
